US FDA’s New ‘Plausible Mechanism’ Pathway Similar To Work Under Prior CBER Leadership

 
• By Sue Sutter
  
Reflection
FDA's new regulatory pathway reflects a similar approach developed by prior leadership.

More from Review Pathways

More from United States